Department of Ophthalmology, School of Medicine, Ewha Womans University Mokdong Hospital, Ewha Womans University, Seoul, Korea.
Graefes Arch Clin Exp Ophthalmol. 2012 May;250(5):679-84. doi: 10.1007/s00417-011-1888-1. Epub 2011 Dec 10.
To evaluate the long-term effects of combined therapy of vitrectomy, intravitreal triamcinolone, and macular laser photocoagulation on diabetic macular edema (DME) unresponsive to prior treatment.
Medical records of 46 eyes of 41 subjects who underwent sequential combined therapy consisting of vitrectomy, intravitreal triamcinolone, and macular laser photocoagulation for refractory DME of non-tractional origin were reviewed. Best-corrected visual acuity (BCVA), central subfield thickness (CST) of macula, and number of additional treatments were analyzed.
Forty eyes of 35 patients completed a 3-year follow-up. The mean (± SD) CSTs before and 6 months, 1 year, 2 years, and 3 years after the administration of combined therapy in these eyes were 499.1 ± 174.9, 224.2 ± 110.2, 273.4 ± 173.5, 237.5 ± 84.2 and 219.4 ± 66.6 µm, respectively (p < 0.001). The mean (± SD) logMAR BCVA before and 6 months, 1 year, 2 years, and 3 years after the combined therapy were 0.82 ± 0.32, 0.69 ± 0.40, 0.63 ± 0.39, 0.61 ± 0.46, and 0.55 ± 0.44, respectively (p < 0.001). Thirty-one of 40 eyes (77.5%) exhibited no recurrence of DME after the combined therapy. No visually significant complications other than progression of lens opacity and elevation of intraocular pressure were noted during the study period.
This study demonstrated the long-term stability and efficacy of the combined therapy described herein for the treatment of refractory DME.
评估玻璃体切割术、玻璃体内曲安奈德和黄斑激光光凝联合治疗对先前治疗无反应的糖尿病性黄斑水肿(DME)的长期效果。
回顾性分析 41 例(46 只眼)非牵引性来源的难治性 DME 患者接受玻璃体切割术、玻璃体内曲安奈德和黄斑激光光凝序贯联合治疗的病历。分析最佳矫正视力(BCVA)、黄斑中心凹下厚度(CST)和追加治疗次数。
35 例患者的 40 只眼完成了 3 年的随访。这些眼在联合治疗前、治疗后 6 个月、1 年、2 年和 3 年的平均(±SD)CST 分别为 499.1±174.9、224.2±110.2、273.4±173.5、237.5±84.2 和 219.4±66.6μm(p<0.001)。联合治疗前和治疗后 6 个月、1 年、2 年和 3 年的平均(±SD)logMAR BCVA 分别为 0.82±0.32、0.69±0.40、0.63±0.39、0.61±0.46 和 0.55±0.44(p<0.001)。联合治疗后,31 只眼(77.5%)DME 无复发。在研究期间,除晶状体混浊进展和眼压升高外,未观察到其他明显的视觉并发症。
本研究表明,本文所述联合治疗难治性 DME 的长期效果稳定且有效。